Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin and Metformin After Intensive Insulin in Type 2 Diabetes
NCT03194945Phase 4Completed
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of linagliptin and metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Proportion of subjects with optimal glycemic control (HbA1c < 7%) at 48 weeks. Started Nov 2017; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03194945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194945.